Experts point to lessons learned from controversy over rofecoxib safety.
Hampton
Tracy
T
D016907:Adverse Drug Reaction Reporting Systems; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects* / Q000191:economics; D006801:Humans; D007783:Lactones / Q000009:adverse effects* / Q000191:economics; D013450:Sulfones / Q000009:adverse effects* / Q000191:economics; D014481:United States; D014486:United States Food and Drug Administration
D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib